Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Trends Microbiol. 2009 Feb;17(2):66-72. doi: 10.1016/j.tim.2008.11.002. Epub 2009 Jan 21.

Preventing biofilms of clinically relevant organisms using bacteriophage.

Author information

  • Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Mail Stop C-16, 1600 Clifton Road, N.E., Atlanta, GA 30333, USA. rld@cdc.gov

Abstract

Biofilms might result in healthcare-associated infections and substantially impact healthcare delivery. Bacteriophage (phage) has been used to treat infectious diseases in humans and there is interest in phage to control biofilms. Phages propagate in their bacterial host and many phages produce depolymerases that hydrolyze biofilm extracellular polymers. Drawbacks of phage to consider include narrow host range, bacterial resistance to phage and phage-encoded virulence genes that can incorporate into the host bacterial genome. The immune system might inactivate phage, and impure phage preparations could contain endotoxin. Phage mixtures or engineered phages could provide effective strategies to overcome these obstacles. Lytic bacteriophages could become a new class of anti-biofilm agents.

PMID:
19162482
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk